H

HeartFlow

Non-invasive cardiac imaging to guide treatment

Director HR Business Partner - Technology

Full-TimePosted on 10/26/2026
$220k - $270k+ Bonus + Equity
Senior, Expert
Bachelor's, Master's
San Francisco, CA, USA
In PersonUp to 25% travel required.
People & HRHR Generalist & Employee Relations

About the job

Requirements
  • A bachelor's degree in human resources, business administration, or a related field is required; a master's degree is preferred.
  • Eight to ten years of progressive human resources experience as an HR business partner or generalist, including at least three years supporting technical functions.
  • A proven track record of partnering with leaders to drive business results through effective HR strategies and initiatives.
  • Experience supporting technical teams, including technology, engineering, research and development, and product teams.
  • Experience with change management.
  • Experience managing employee relations matters, including investigation management.
  • Up to 25% travel is required.
  • Strong business acumen and the ability to influence and implement HR strategies that support company growth objectives.
  • A deep understanding of HR best practices, trends, and emerging technologies.
Responsibilities
  • Partner with Technology business leaders in research and development and Product to understand strategic objectives and align HR strategies with business goals.
  • Drive initiatives to enhance organizational effectiveness and operational efficiency, including organizational design, change management, employee relations, and succession planning.
  • Collaborate with the HR team to develop and implement best practices.
  • Develop and implement strategies to foster a high-performance culture that promotes employee engagement, diversity, equity, and inclusion.
  • Analyze HR metrics and data to provide leaders with insights and recommendations on workforce trends, talent management strategies, and organizational health.
  • Ensure compliance with relevant laws and regulations and uphold ethical standards in all HR practices.

About the company

HeartFlow provides a non-invasive cardiac test that helps doctors visualize a patient’s coronary arteries to diagnose and plan treatment for heart disease. It uses a proprietary set of analyses—FFRCT Analysis, RoadMap Analysis, Plaque Analysis, and HeartFlow Planner—to create a detailed, patient-specific visualization from imaging data, enabling clinicians to assess blood flow and plaque without surgery. This approach reduces the need for invasive procedures, lowers risk for patients, and can cut costs for healthcare providers. Compared with traditional methods, HeartFlow offers validated, FDA-cleared tools that integrate multiple analyses into one platform, giving physicians a clearer, data-driven basis for diagnosis and treatment decisions. The company’s goal is to improve cardiovascular care by making safer, more efficient diagnosis and treatment planning widely available in hospitals and clinics around the world.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Francisco, California

Founded

2010

Get referred to HeartFlow

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue rose 48% to $64.1 million, lifting full-year guidance.
  • Plaque revenue reached $7.8 million in Q2 2026, becoming a second growth engine.
  • Gross margin hit 83%, showing strong operating leverage and software economics.

What critics are saying

  • Cleerly’s July 2026 plaque clearance and FFR-CT code pressure HeartFlow pricing power.
  • The April 2026 Texas patent suit against Cleerly drains management time and cash.
  • Growth depends on reimbursement and clinician adoption; any payer pullback hits 2027 revenue fast.

What makes HeartFlow unique

  • HeartFlow One unifies FFRCT, Plaque Analysis, and PCI Navigator in one workflow.
  • July 2026 Plaque Staging uses total plaque volume with up to 16 years follow-up.
  • HeartFlow holds the only FDA-cleared AI plaque tool with reported 95% IVUS agreement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Stock Options
  • 401(k) Company Match

Growth & Insights and Company News

6 month growth

-1%

1 year growth

0%

2 year growth

-1%
Yahoo Finance
Oct 25th, 2026
Three small-cap AI stocks to watch: CeriBell, HeartFlow and Penguin Solutions

Simply Wall St has named three small-cap AI stocks to watch in October 2026, as financiers warn that high valuations and concentrated AI exposure could feed the next market downturn. CeriBell, a Sunnyvale medtech company, uses AI to detect seizures from brainwave data. It generated about $102 million from diagnostic kits and equipment, all in the US, and has a market value of roughly $1.0 billion. HeartFlow turns coronary CT scans into AI-based decision tools for cardiologists. It posted about $212 million in revenue and has a market value of roughly $4.9 billion. Its Plaque Analysis moves to a Category 1 CPT code in 2026, with defined Medicare payment rates. Penguin Solutions supplies AI infrastructure. Its Integrated Memory unit brought in about $924 million, Advanced Computing about $559 million, and Optimized LED about $249 million. Its market value is near $3.2 billion.

Yahoo Finance
Sep 15th, 2026
HeartFlow CEO sells 38,900 shares for $1.8M as stock nears 52-week high

HeartFlow CEO John C.M. Farquhar sold 38,900 shares of common stock for $1.8 million, according to a 14 September 2026 SEC filing. The shares were sold at a weighted average price of $46.78, with individual trades ranging from $45.43 to $47.78. The transaction was conducted under a Rule 10b5-1 trading plan established on 12 September 2025. Following the sale, Farquhar retains approximately 322,000 shares, representing 0.37% of the company, plus derivative securities. HeartFlow develops AI-powered cardiac diagnostic solutions that create three-dimensional digital replicas of patient hearts from CT scans. The company has a market capitalisation of $4.3 billion and generated $212.1 million in trailing 12-month revenue, whilst recording a net loss of $118.4 million.

Yahoo Finance
Aug 20th, 2026
HeartFlow CMO sells $380K in shares as stock surges 35% in one year

HeartFlow's Chief Medical Officer Campbell Rogers sold 9,219 shares on 17 August 2026 for approximately $380,100, according to an SEC Form 4 filing. The transaction was executed under a Rule 10b5-1 trading plan adopted in December 2025. Rogers retains a significant stake in the company, holding 86,459 shares directly and 145,540 shares indirectly through various trusts, representing a 0.27% ownership. He also maintains 82,972 options vesting monthly through August 2029. HeartFlow's shares closed at $45.23 on 18 August 2026, achieving a 35% one-year return as of the transaction date. The company, which develops AI-powered cardiac diagnostic solutions, has a market capitalisation of $3.9 billion with trailing twelve-month revenue of $212.1 million and a net loss of $118.4 million.

Yahoo Finance
Aug 18th, 2026
HeartFlow raises 2026 guidance to $246M–$250M revenue on 48% Q2 growth

Heartflow reported second quarter 2026 revenue of $64.1 million, up 48% year-over-year, driven by increased US case volumes for its FFRCT and Plaque products. The AI-powered coronary artery disease diagnostics company posted a gross margin of 83.0% and a net operating loss of $17.9 million. The company raised its full-year revenue guidance to $246 million to $250 million, representing approximately 40% to 42% growth, up from previous guidance of $228 million to $232 million. It also increased its non-GAAP gross margin outlook to approximately 82% from 81%. CEO John Farquhar said the Plaque product is emerging as a "meaningful second growth engine" alongside the core FFRCT business, helping win new accounts and deepen physician utilisation.

Yahoo Finance
Aug 14th, 2026
HeartFlow revenue surges 48% to $64.1M as plaque product drives record growth

HeartFlow reported second quarter 2026 revenue of $64.1 million, up 48% year over year. US revenue grew 51% to $59.6 million, marking the company's fastest growth in eight quarters. The medical technology firm's Plaque product generated $7.8 million in revenue, exceeding expectations. Total global revenue cases reached 84,491, up 74% year over year. Gross margin expanded to 83.3% from 75.6% in the prior year period, driven by AI efficiencies and higher-margin Plaque mix. HeartFlow raised its full-year 2026 revenue guidance to $246 million to $250 million, representing 40% to 42% growth. The company also increased its Plaque revenue outlook to $29 million to $31 million. The non-GAAP operating loss narrowed to $7.9 million from $11.5 million last year. HeartFlow ended the quarter with $246.8 million in cash and investments.